当前位置: 首页 >> 检索结果
21. Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis.
作者: Josef S Smolen.;Peter C Taylor.;Yoshiya Tanaka.;Tsutomu Takeuchi.;Motomu Hashimoto.;Carlos Cara.;Bernard Lauwerys.;Nicola Tilt.;Baran Ufuktepe.;Ricardo M Xavier.;Alejandro Balsa.;Jeffrey R Curtis.;Ted R Mikuls.;Michael Weinblatt.
来源: Rheumatology (Oxford). 2024年63卷11期3015-3024页
To assess the impact of baseline RF level on drug concentrations and efficacy of certolizumab pegol [CZP; TNF inhibitor (TNFi) without a crystallizable fragment (Fc)] and adalimumab (ADA; Fc-containing TNFi) in patients with RA.
22. Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials.
作者: Ioannis Parodis.;Julius Lindblom.;Roger A Levy.;Margherita Zen.;Nursen Cetrez.;Alvaro Gomez.;Shereen Oon.;Christine Henning.;Munther Khamashta.;Holly A Quasny.;Deven Chauhan.;Anca Askanase.;Ronald van Vollenhoven.;Mandana Nikpour.
来源: Lancet Rheumatol. 2024年6卷11期e751-e761页
Disease remission or low disease activity are key treatment targets for patients with systemic lupus erythematosus (SLE). Pivotal trials of belimumab were conducted before the introduction of these targets. In this study, we aimed to pool data across trials to assess attainment of remission and low disease activity in a large, racially and culturally diverse patient population with SLE.
23. A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment.
作者: Atul Deodhar.;Alan J Kivitz.;Marina Magrey.;Jessica A Walsh.;Philip J Mease.;Maria Greenwald.;Farid Kianifard.;Chelsea Elam.;Gopi M Bommidi.;Adam Winseck.;Lianne S Gensler.
来源: Rheumatology (Oxford). 2025年64卷4期1864-1872页
To investigate the clinical response at week 52 in patients with AS who received secukinumab 300 vs 150 mg after inadequate response to 150 mg at week 16.
24. Enhanced surveillance for the detection of psoriatic arthritis in a UK primary care psoriasis population: results from the TUDOR trial.
作者: Neil McHugh.;William Tillett.;Philip Helliwell.;Jonathan Packham.;Howard Collier.;Claire Davies.;Myka Ransom.;Laura Coates.;Sarah T Brown.
来源: Rheumatology (Oxford). 2025年64卷4期1750-1759页
Our objective was to determine whether early detection of undiagnosed PsA in a primary care psoriasis population improves outcome in physical function at 24 months post-registration.
25. The impact of periodontitis and periodontal treatment on rheumatoid arthritis outcomes: an exploratory clinical trial.
作者: Daniela S Silva.;Charlotte de Vries.;João Rovisco.;Sara Serra.;Marta Kaminska.;Piotr Mydel.;Karin Lundberg.;José António P da Silva.;Isabel P Baptista.
来源: Rheumatology (Oxford). 2025年64卷4期1679-1688页
Studies suggest RA patients could benefit from periodontal treatment. However, published data are inconsistent, and there is a need for better-controlled research. Our study aims to address these limitations.
26. A double-blind, placebo-controlled, randomized multiple dose phase 1b trial of a CDK4/6 inhibitor, TCK-276, in patients with active rheumatoid arthritis.
作者: Daisuke Tasaki.;Kazuoki Tsuruda.;Shosho Sun.;Yoshinori Tsumura.;Satoshi Asano.;Yuki Suzuki.;Shunsuke Tsujimoto.;Daishiro Miura.;Hiroaki Sato.
来源: Rheumatology (Oxford). 2025年64卷3期1036-1044页
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics and efficacy (as an exploratory endpoint) of TCK-276, a novel CDK4/6 inhibitor, after multiple oral doses for 7 days in patients with active RA.
27. Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial.
作者: Claudia Worth.;M Hussein Al-Mossawi.;Joanne Macdonald.;Benjamin A Fisher.;Antoni Chan.;Raj Sengupta.;Jonathan Packham.;Karl Gaffney.;Nicola Gullick.;Jonathan A Cook.;Tim H Corn.;James Teh.;Pedro M Machado.;Peter C Taylor.;Paul Bowness.
来源: Lancet Rheumatol. 2024年6卷8期e537-e545页
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a proinflammatory cytokine overproduced in several inflammatory and autoimmune diseases, including axial spondyloarthritis. Namilumab is a human IgG1 monoclonal anti-GM-CSF antibody that potently neutralises human GM-CSF. We aimed to assess the efficacy of namilumab in participants with moderate-to-severe active axial spondyloarthritis.
28. One-year effectiveness of long-term exercise therapy in people with axial spondyloarthritis and severe functional limitations.
作者: Maria A T van Wissen.;Cornelia H M van den Ende.;Maaike G J Gademan.;Max M H Teuwen.;Wilfred F Peter.;Elien A M Mahler.;Dirkjan van Schaardenburg.;Floris A van Gaalen.;Anneke Spoorenberg.;Wilbert B van den Hout.;Astrid M van Tubergen.;Theodora P M Vliet Vlieland.;Salima F E van Weely.
来源: Rheumatology (Oxford). 2025年64卷4期1817-1825页
To evaluate the effectiveness of long-term, personalized, supervised exercise therapy on functional ability compared with usual care in people with axial spondyloarthritis (axSpA) and severe functional limitations.
29. Supporting self-management of low back pain with an internet intervention with and without telephone support in primary care (SupportBack 2): a randomised controlled trial of clinical and cost-effectiveness.
作者: Adam W A Geraghty.;Taeko Becque.;Lisa C Roberts.;Jonathan C Hill.;Nadine E Foster.;Lucy Yardley.;Beth Stuart.;David A Turner.;Elaine Hay.;Gareth Griffiths.;Frances Webley.;Lorraine Durcan.;Alannah Morgan.;Stephanie Hughes.;Sarah Bathers.;Stephanie Butler-Walley.;Simon Wathall.;Gemma Mansell.;Malcolm White.;Firoza Davies.;Paul Little.
来源: Lancet Rheumatol. 2024年6卷7期e424-e437页
Low back pain is prevalent and a leading cause of disability. We aimed to determine the clinical and cost-effectiveness of an accessible, scalable internet intervention for supporting behavioural self-management (SupportBack).
30. Ramosetron as an add-on therapy for refractory fibromyalgia: a randomized, double-blind, placebo-controlled trial.
作者: Dong-Jin Park.;Hyemin Jeong.;Sung-Eun Choi.;Ji-Hyoun Kang.;Jung-Kil Lee.;Shin-Seok Lee.
来源: Rheumatology (Oxford). 2024年63卷9期2372-2378页
This study aimed to assess the efficacy and safety of intravenous ramosetron for pain relief in patients with fibromyalgia (FM) unresponsive to conventional treatments.
31. Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies.
作者: Laure Gossec.;Ana-Maria Orbai.;Maarten de Wit.;Laura C Coates.;Alexis Ogdie.;Barbara Ink.;Jason Coarse.;Jérémy Lambert.;Vanessa Taieb.;Dafna D Gladman.
来源: Rheumatology (Oxford). 2024年63卷9期2399-2410页
To evaluate 1-year bimekizumab efficacy in PsA from the patient perspective using the 12-item PsA Impact of Disease (PsAID-12) questionnaire.
32. Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
作者: Carl S Goodyear.;Amit Patel.;Eleanor Barnes.;Michelle Willicombe.;Stefan Siebert.;Thushan I de Silva.;John A Snowden.;Sean H Lim.;Sarah J Bowden.;Lucinda Billingham.;Alex Richter.;Miles Carroll.;Edward J Carr.;Rupert Beale.;Daniel Rea.;Helen Parry.;Sarah Pirrie.;Zixiang Lim.;Jack Satsangi.;Susanna J Dunachie.;Gordon Cook.;Paul Miller.;Neil Basu.;Ashley Gilmour.;Anne-Marie Hodgkins.;Lili Evans.;Ana Hughes.;Stephanie Longet.;Georgina Meacham.;Kwee L Yong.;Matthew J A'Hearne.;Mickey B C Koh.;Siobhan O Burns.;Kim Orchard.;Caron Paterson.;Graham McIlroy.;Sam M Murray.;Tina Thomson.;Stavros Dimitriadis.;Lyndsey Goulston.;Samantha Miller.;Victoria Keillor.;Maria Prendecki.;David Thomas.;Amanda Kirkham.;Iain B McInnes.;Pamela Kearns.; .
来源: Lancet Rheumatol. 2024年6卷6期e339-e351页
The humoral and T-cell responses to booster COVID-19 vaccine types in multidisease immunocompromised individuals who do not generate adequate antibody responses to two COVID-19 vaccine doses, is not fully understood. The OCTAVE DUO trial aimed to determine the value of third vaccinations in a wide range of patients with primary and secondary immunodeficiencies.
33. Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind, placebo-controlled trial.
作者: Jin Kyun Park.;Miriam Kim.;Ji In Jung.;Ju Yeon Kim.;Heejin Jeong.;Jun Won Park.;Kevin L Winthrop.;Eun Bong Lee.
来源: Lancet Rheumatol. 2024年6卷6期e352-e360页
The adjuvanted herpes zoster subunit vaccine has shown good efficacy and safety in the general population. However, its effectiveness has not been comprehensively assessed in patients with systemic lupus erythematosus (SLE). This study aimed to evaluate the immunogenicity and safety of the adjuvanted herpes zoster subunit vaccine in patients with SLE.
34. Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial.
作者: Andreu Fernández-Codina.;Tatiana Nevskaya.;Murray Baron.;C Thomas Appleton.;Matthew J Cecchini.;Amanda Philip.;Maha El-Shimy.;Louise Vanderhoek.;Iago Pinal-Fernández.;Janet E Pope.
来源: Rheumatology (Oxford). 2025年64卷3期1476-1481页
We explored the efficacy and safety of brentuximab vedotin, a chimeric anti-CD30 antibody drug conjugate, in patients with severe active diffuse cutaneous systemic sclerosis (dcSSc).
35. Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.
作者: Kaja E Kjørholt.;Nina Paulshus Sundlisæter.;Anna-Birgitte Aga.;Joseph Sexton.;Inge C Olsen.;Hallvard Fremstad.;Cristina Spada.;Tor Magne Madland.;Christian A Høili.;Gunnstein Bakland.;Åse Lexberg.;Inger Johanne Widding Hansen.;Inger Myrnes Hansen.;Hilde Haukeland.;Maud-Kristine Aga Ljoså.;Ellen Moholt.;Till Uhlig.;Tore K Kvien.;Daniel H Solomon.;Désirée van der Heijde.;Espen A Haavardsholm.;Siri Lillegraven.
来源: Lancet Rheumatol. 2024年6卷5期e268-e278页
Tapering of disease-modifying antirheumatic drugs (DMARDs) to drug-free remission is an attractive treatment goal for patients with rheumatoid arthritis, although long-term effects of tapering and withdrawal remain unclear. We compared 3-year risks of flare between three conventional synthetic DMARD treatment strategies in patients with rheumatoid arthritis in sustained remission.
36. Responsiveness and sensitivity of PROMs to change in disease activity status in early and established rheumatoid arthritis.
作者: Agnes E M Looijen.;Elise van Mulligen.;Harald E Vonkeman.;Annette H M van der Helm-van Mil.;Pascal H P de Jong.
来源: Rheumatology (Oxford). 2025年64卷3期1060-1067页
To determine whether patient-reported outcome measures (PROMs) capturing activity limitations, health impact, pain, fatigue and work ability are responsive and sensitive to changes in disease activity status in patients with early and established RA.
37. Long-term clinical outcomes in early rheumatoid arthritis that was treated-to-target in the BeSt and IMPROVED studies.
作者: Sascha Louise Heckert.;Johanna M Maassen.;Isabell Nevins.;Paul Baudoin.;Gerda M Steup-Beekman.;Tom W J Huizinga.;Sytske Anne Bergstra.;Cornelia F Allaart.
来源: Rheumatology (Oxford). 2025年64卷3期1052-1059页
To assess disease outcomes after 20 and 12 years of patients with RA or undifferentiated arthritis (UA), treated-to-target in the BeSt and IMPROVED trials.
38. Efficacy of methylprednisolone in very early systemic sclerosis: results of the 'Hit Hard and Early' randomized controlled trial.
作者: Brigit E Kersten.;Jacqueline M J Lemmers.;Amber Vanhaecke.;Arthiha Velauthapillai.;Wieneke M T van den Hombergh.;Frank H J van den Hoogen.;Cornelia H M van den Ende.;Vanessa Smith.;Madelon C Vonk.
来源: Rheumatology (Oxford). 2025年64卷3期1261-1269页
We hypothesized that glucocorticoids would induce remission in very early systemic sclerosis (SSc) patients by inhibition of inflammation driving the disease. We examined the efficacy and safety of methylprednisolone in very early SSc.
39. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis.
作者: Hermine I Brunner.;Nicolino Ruperto.;Athimalaipet V Ramanan.;Gerd Horneff.;Kirsten Minden.;Inmaculada Calvo Penades.;Ekaterina Alexeeva.;Gavin Cleary.;Sara M Stern.;Isabelle Kone-Paut.;María Del Rocío Maldonado Velázquez.;C Egla Rabinovich.;Agustin Remesal.;Clovis Artur Silva.;Irina Nikishina.;Mauro Zucchetto.;Laura Brockwell.;Oliver Gordon.;Sandra Nagel.;Fabrizio De Benedetti.; .
来源: Rheumatology (Oxford). 2024年63卷9期2535-2546页
To investigate the safety and efficacy of subcutaneous tocilizumab (SC-TCZ) treatment in a long-term extension (LTE) of clinical trials in polyarticular or systemic juvenile idiopathic arthritis (pJIA or sJIA).
40. Economic evaluation of a trial exploring the effects of a web-based support tool for parents of children with juvenile idiopathic arthritis.
作者: Chris Flood.;Shashivadan P Hirani.;Kathleen Mulligan.;Jo Taylor.;Sally Harris.;Lucy R Wedderburn.;Stanton P Newman.
来源: Rheumatology (Oxford). 2024年63卷SI2期SI136-SI142页
To explore the cost-effectiveness of a web-based support tool for parents of children with Juvenile idiopathic arthritis.
|